These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 35608658)

  • 21. The Impact of Disease-Modifying Therapy Access Barriers on People With Multiple Sclerosis: Mixed-Methods Study.
    Simacek KF; Ko JJ; Moreton D; Varga S; Johnson K; Katic BJ
    J Med Internet Res; 2018 Oct; 20(10):e11168. PubMed ID: 30377144
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long term effect of delayed treatment on disability in patients with paediatric onset multiple sclerosis: A prospective Danish cohort study.
    Kopp TI; Blinkenberg M; Petersen T; Sorensen PS; Magyari M
    Mult Scler Relat Disord; 2020 May; 40():101956. PubMed ID: 32007654
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Paradigm shifts in multiple sclerosis management: Implications for daily clinical practice.
    Bourre B; Casez O; Ciron J; Gueguen A; Kwiatkowski A; Moisset X; Montcuquet A; Ayrignac X
    Rev Neurol (Paris); 2023 Apr; 179(4):256-264. PubMed ID: 36621364
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of relapsing multiple sclerosis - recommendations of the Croatian Neurological Society.
    Habek M; Adamec I; Barun B; Bašić Kes V; Bogoje Raspopović A; Duka Glavor K; Gabelić T; Grzinčić T; Jukić M; Jurašić MJ; Kiđemet-Piskač S; Komšo M; Rimac J; Lazibat I; Lukić B; Marčinko A; Matijaca M; Ratković M; Šapina L; Vuletić V; Mirošević Zubonja T; Krbot Skorić M
    Croat Med J; 2022 Aug; 63(4):379-388. PubMed ID: 36046935
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incorporating patients' preferences in the value assessment of disease-modifying therapies for multiple sclerosis: a narrative review.
    Ngorsuraches S; Poudel N
    Expert Rev Pharmacoecon Outcomes Res; 2021 Apr; 21(2):183-195. PubMed ID: 33472451
    [No Abstract]   [Full Text] [Related]  

  • 26. As time goes by: Treatment challenges in elderly people with multiple sclerosis.
    Gelibter S; Saraceno L; Pirro F; Susani EL; Protti A
    J Neuroimmunol; 2024 Jun; 391():578368. PubMed ID: 38761652
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative Efficacy of Relapsing Multiple Sclerosis Therapies: Model-Based Meta-Analyses for Confirmed Disability Accumulation and Annualized Relapse Rate.
    Hennessy B; Zierhut ML; Kracker H; Keenan A; Sidorenko T
    Mult Scler Relat Disord; 2022 Aug; 64():103908. PubMed ID: 35803162
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of Disease-Modifying Therapies on COVID-19 Vaccination Efficacy in Multiple Sclerosis Patients: A Comprehensive Review.
    Jamali E; Shapoori S; Farrokhi MR; Vakili S; Rostamzadeh D; Iravanpour F; Tavakoli Oliaee R; Jafarinia M
    Viral Immunol; 2023; 36(6):368-377. PubMed ID: 37276047
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Teriflunomide vs injectable disease modifying therapies for relapsing forms of MS.
    Vermersch P; Oh J; Cascione M; Oreja-Guevara C; Gobbi C; Travis LH; Myhr KM; Coyle PK
    Mult Scler Relat Disord; 2020 Aug; 43():102158. PubMed ID: 32470857
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evolution of Disease Modifying Therapy Benefits and Risks: An Argument for De-escalation as a Treatment Paradigm for Patients With Multiple Sclerosis.
    Vollmer BL; Wolf AB; Sillau S; Corboy JR; Alvarez E
    Front Neurol; 2021; 12():799138. PubMed ID: 35145470
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Highly effective disease-modifying treatment as initial MS therapy.
    Schmierer K; Sørensen PS; Baker D
    Curr Opin Neurol; 2021 Jun; 34(3):286-294. PubMed ID: 33840776
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disease modifying therapies continue to drive up health care cost among individuals with multiple sclerosis.
    Kim Y; Krause TM; Blum P; Freeman L
    Mult Scler Relat Disord; 2019 May; 30():69-75. PubMed ID: 30738875
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [New treatments and strategy in multiple sclerosis].
    Guéguen A; Gout O
    Rev Prat; 2016 Jan; 66(1):44-50. PubMed ID: 30512399
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The evolution of multiple sclerosis disease-modifying therapies: An update for pharmacists.
    Edinger A; Habibi M
    Am J Health Syst Pharm; 2024 Jan; 81(2):37-55. PubMed ID: 37777869
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patient perspective on decisions to switch disease-modifying treatments in relapsing-remitting multiple sclerosis.
    Manzano A; Eskyté I; Ford HL; Pavitt SH; Potrata B; Schmierer K; Chataway J; Webb EJD; Meads D; Pepper G; Bekker HL
    Mult Scler Relat Disord; 2020 Nov; 46():102507. PubMed ID: 32979733
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study.
    Iaffaldano P; Lucisano G; Manni A; Paolicelli D; Patti F; Capobianco M; Brescia Morra V; Sola P; Pesci I; Lus G; De Luca G; Lugaresi A; Cavalla P; Montepietra S; Maniscalco GT; Granella F; Ragonese P; Vianello M; Brambilla L; Totaro R; Toscano S; Malucchi S; Petracca M; Moiola L; Ferraro D; Lepore V; Mosconi P; Ponzio M; Tedeschi G; Comi G; Battaglia MA; Filippi M; Amato MP; Trojano M;
    Neurol Neuroimmunol Neuroinflamm; 2022 Mar; 9(2):. PubMed ID: 35046084
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Approaches and challenges in the diagnosis and management of secondary progressive multiple sclerosis: A Central Eastern European perspective from healthcare professionals.
    Boyko A; Therapontos C; Horakova D; Szilasiová J; Kalniņa J; Kolontareva J; Gross-Paju K; Selmaj K; Sereike I; Milo R; Gabelić T; Rot U
    Mult Scler Relat Disord; 2021 May; 50():102778. PubMed ID: 33592384
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early Aggressive Treatment Approaches for Multiple Sclerosis.
    Simpson A; Mowry EM; Newsome SD
    Curr Treat Options Neurol; 2021; 23(7):19. PubMed ID: 34025110
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent trends in disease-modifying therapy use and associated sickness absence and disability pension among people with multiple sclerosis in Sweden.
    Teni FS; Machado A; Fink K; Gyllensten H; Hillert J; Friberg E
    Mult Scler; 2024 Mar; 30(3):419-431. PubMed ID: 38243631
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is there a change of paradigm towards more effective treatment early in the course of apparent high-risk MS?
    Fernández Ó
    Mult Scler Relat Disord; 2017 Oct; 17():75-83. PubMed ID: 29055479
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.